Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 4, 2018--Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced the appointment of Meryl Zausner, a seasoned biopharmaceutical executive, to its Board of Directors. Ms. Zausner brings decades of financial and operational leadership experience in the pharmaceutical industry.
“Meryl Zausner is a highly accomplished financial and strategic leader, and I am delighted to welcome her to the Seres Board,” said Roger J. Pomerantz, M.D., President, CEO and Chairman of Seres. “Meryl’s extensive biopharmaceutical and oncology expertise will be an important asset to Seres as we continue to advance our extensive pipeline of microbiome therapeutic candidates.”
Ms. Zausner commented: “I am eager to contribute to Seres’ progress as it advances the development of microbiome therapeutics, a promising new treatment modality with potential to address a wide range of serious diseases.”
Meryl Zausner previously served as chief financial and administrative officer of Novartis Pharmaceuticals Corporation and a member of the U.S. Pharmaceutical Executive Committee and Global Finance Leadership Team. At Novartis, she was instrumental in the launch of the Oncology Business Unit, as well as the company’s shared services organization. Ms. Zausner was a member of the Novartis Global Oncology Leadership Team and played a key role in developing and commercializing leading therapies including Gleevec® (imatinib). Ms. Zausner is also currently a board member and chair of the audit committee for Neon Therapeutics, Inc. and the Multiple Myeloma Research Foundation. Ms. Zausner received a B.S. in accounting and economics from the University at Albany, SUNY.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq:MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate ulcerative colitis. Seres is developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. Seres is also developing SER-401 to augment the efficacy of immuno-oncology treatment. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including Ms. Zausner’s potential contribution to the Company.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; our unproven approach to therapeutic intervention; the lengthy, expensive, and uncertain process of clinical drug development; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; our lack of experience in manufacturing, selling, marketing, and distributing our product candidates; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; our ability to retain key personnel and to manage our growth; the potential volatility of our common stock; and our management and principal stockholders have the ability to control or significantly influence our business. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on August 2, 2018 and our other reports filed with the SEC, including the Quarterly Report we intend to file later today, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180904005085/en/
CONTACT: IR and PR Contact:
Carlo Tanzi, Ph.D., 617-203-3467
Vice President, Investor Relations and Corporate Communications
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY INFECTIOUS DISEASES PHARMACEUTICAL OTHER HEALTH
SOURCE: Seres Therapeutics, Inc.
Copyright Business Wire 2018.
PUB: 09/04/2018 07:00 AM/DISC: 09/04/2018 07:01 AM